67 WALL STREET, New York - November 19, 2009 - The Wall Street Transcript has recently published its Q3 2009 Medical Devices Report offering a review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs, Equity Analysts and Money Managers. The full issue is available via The Wall Street Transcript Online.

Topics covered: Developments in the Medical Industry Industry -- New FDA Approval For Medical Devices -- Negative Price Pressure -- The Inject Mix -- Hospital Capital Spending Behavior -- Growth Due To Healthcare Reform -- Rate of Growth In Product Reliability -- Execution of Device Manufacturing Management -- Clinical Trials Success Rate -- Managing Medical Device Recalls -- Major Turnarounds In Medical Device Marketplace -- Demonstrating Medication Adherence -- Undervaluation For Certain Medical Device Stocks -- Effects Of Weakening Dollar -- Medical Device Market Share Analysis

Companies include: Medtronic (MDT); Boston Scientific (BSX); Greatbatch (GB); Vascular Solutions (VASC); AngioDynamics (ANGO); St. Jude Medical (STJ); Edwards Lifesciences (EW); Stryker (SYK); Zimmer Holdings (ZMH); Abbott Laboratories (ABT); Johnson and Johnson (JNJ); Baxter International (BAX); Thoratec (THOR); HeartWare (HTWR); Hill-Rom Holdings (HRC); Accuray (ARAY); Smith and Nephew (SN.L); Wright Medical (WMGI); NuVasive (NUVA); TranS1 (TSON); Becton, Dickinson (BDX); C.R. Bard (BCR); Covidien (COV); CareFusion (CFN);Edwards Lifesciences (EW); Zimmer (ZMH); Nanosphere (NSPH)

In the following brief excerpt from just one of the in depth interviews in the Special Report, an award winning equity analyst discusses the outlook for the sector and for investors.

Kristen Stewart is a Vice President and Senior Analyst in the equity research department at Credit Suisse, where she covers the medical supplies and devices industry. Ms. Stewart joined Credit Suisse in May 2007 after spending six years within the research department at UBS. Prior to UBS, Ms. Stewart worked at PricewaterhouseCoopers within the Financial Advisory Services and Business Assurance groups. Ms. Stewart is a graduate of Villanova University with a B.S. in accountancy and a BBA with a major in finance. She is a CFA charterholder.

TWST: Are there any companies that are longer-term turnaround prospects?

Ms. Stewart: I would say that Covidien (COV) is still in the process of turning itself around from when it was being managed under Tyco (TYC). I think Boston Scientific (BSX) certainly fits that category. They have had a lot of challenges integrating the Guidant acquisition, and they are attempting to stage a turnaround within its operations and its financials. Beyond those two names, CareFusion (CFN) is another company that has recently spun out of Cardinal Health. Typically what we see with spinoffs are companies that have been not as optimally managed or not as optimally run from a capital perspective, and that could be another potential turnaround play as well.

TWST: As you talk to management, what's the level of confidence at this moment?

Ms. Stewart: I think management are very confident in the factors that they control, their company decisions, but they are less confident in things obviously outside of their control. There is a lot of concern with senior management of the companies that I cover, as well as in health care broadly, when it comes to what is transpiring on health care reform side. They are, I think, a little bit more uneasy about what has been discussed and what could potentially come out of health care reform and tax reform as well. I think the lack of visibility has been a major issue for a lot of company managers as well as investors.

Note: Opinions and recomendations are as of 09/09/09.

KRISTEN M. STEWART

Vice President and Senior Analyst

Credit Suisse

The following companies have been an investment banking department client of Credit Suisse in the past 12 months: CFN, NSPH, ZMH, COV, BAX, BDX, BSX, and MDT. The following companies have been a non-investment banking department client of Credit Suisse in the past 12 months: ZMH and BAX. Credit Suisse has recieved compensation from the following companies in the past 12 months: ZMH and BAX. The following companies is expected to be an investment banking client of Credit Suisse or its affiliates in the next three months: CFN, NSPH, ZMH, SYK, EW, COV, BAX, BDX, BSX, BCR and MDT.

The Wall Street Transcript is a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online .

The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations.

For Information on subscribing to The Wall Street Transcript, please call 800/246-7673